Trials / Completed
CompletedNCT00189904
Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in HIV Infected Patients
A Multicenter, Open-label Phase I/II Study to Evaluate Safety and Immunogenicity of MVA-BN® Smallpox Vaccine in HIV Infected Subjects (CD4 Counts >350 / µl) and Healthy Subjects With and Without Previous Smallpox Vaccination
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 151 (actual)
- Sponsor
- Bavarian Nordic · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- —
Summary
The purpose of this study is to gather information on the safety and immunogenicity of an investigational smallpox vaccine in HIV infected populations.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | IMVAMUNE (MVA-BN) |
Timeline
- Start date
- 2005-07-01
- First posted
- 2005-09-19
- Last updated
- 2012-09-28
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00189904. Inclusion in this directory is not an endorsement.